Schott Pharma AG & CO KGaA (OTCPK:SHTPY)

Q2 2026 SCHOTT Pharma AG & Co KgaA Earnings Call Transcript

May 13, 2026 / 09:00 AM GMT

Release Date Price: $4.37

Transcript

Key Points

Positve

Schott Pharma AG & CO KGaA (WBO:1SXP) reported a resilient performance in the first half of the financial year 2026, with revenues reaching EUR 488 million, representing growth of 2.3% at constant currencies.
The Drug Containment Solutions (DCS) segment showed strong growth, with revenues increasing by 8.3% at constant currencies, driven by high-value solutions.
The company launched Cartridge BioPure, a new sterile glass cartridge for complex biologics, addressing key industry trends and customer needs.
Free cash flow more than doubled year-over-year to EUR 45.4 million, driven by working capital improvements.
Schott Pharma AG & CO KGaA (WBO:1SXP) confirmed its guidance for the full financial year 2026, expecting revenue growth of 2% to 5% at constant currencies and an EBITDA margin of around 27%.

Negative

The Drug Delivery Systems (DDS) segment faced temporary headwinds, with revenues down 5.4% at constant currencies due to weakness in polymer syringes and lower glass syringe volumes.
Group EBITDA in Q2 2026 declined by around EUR 7 million year-over-year, resulting in a lower EBITDA margin of 26% compared to 28.5% in Q2 2025.
A one-off inventory impairment on a customer-specific glass syringe negatively impacted DDS profitability.
The financial result showed a negative EUR 4.1 million, despite improvements due to lower interest expenses.
Net income decreased to EUR 64.4 million from EUR 68.1 million in the previous year, reflecting the impact of the one-off impairment and higher depreciation.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

1SXP.DE - SCHOTT Pharma AG & Co KgaA
Q2 2026 SCHOTT Pharma AG & Co KgaA Earnings Call
May 13, 2026 / 09:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, everyone, and welcome to Schott's Pharma's earnings call for the first half of financial year 2026.

My name is Tobias Erfurt, Head of Investor Relations, and I will guide you through today's session.

With me on the call are our CEO, Christian Mears, and our CFO, Reinhard Meyer.

As a reminder, and as announced in November 2025, Christian joined Schott Pharma as new CEO on May 1.

Christian, welcome once again. We are very happy to have you with us, and together with Reinhardt, you bring extensive experience and fresh perspectives to Schott Farmer.

Christian will begin with a brief introduction and a business update, followed by Reinhardt, who will walk

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.